126 related articles for article (PubMed ID: 11881837)
1. Naftidrofuryl in the treatment of vascular dementia.
Möller HJ; Hartmann A; Kessler C; Rainer M; Brown T; Gamand S; Lehert P
Eur Arch Psychiatry Clin Neurosci; 2001 Dec; 251(6):247-54. PubMed ID: 11881837
[TBL] [Abstract][Full Text] [Related]
2. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial.
Emeriau JP; Lehert P; Mosnier M
Clin Ther; 2000 Jul; 22(7):834-44. PubMed ID: 10945510
[TBL] [Abstract][Full Text] [Related]
4. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
Small G; Erkinjuntti T; Kurz A; Lilienfeld S
CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
[TBL] [Abstract][Full Text] [Related]
5. Naftidrofuryl in the treatment of mild senile dementia. A double-blind study.
Grossmann WM; Standl A; May U; van Laak HH; Hirche H
Pharmacopsychiatry; 1990 Nov; 23(6):265-73. PubMed ID: 2284328
[TBL] [Abstract][Full Text] [Related]
6. Naftidrofuryl in quality of life (NIQOL). A Belgian study.
D'Hooge D; Lehert P; Clement DL
Int Angiol; 2001 Dec; 20(4):288-94. PubMed ID: 11782694
[TBL] [Abstract][Full Text] [Related]
7. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
Kieffer E; Bahnini A; Mouren X; Gamand S
Int Angiol; 2001 Mar; 20(1):58-65. PubMed ID: 11342997
[TBL] [Abstract][Full Text] [Related]
8. Naftidrofuryl: a review of its use in the treatment of intermittent claudication.
Goldsmith DR; Wellington K
Drugs Aging; 2005; 22(11):967-77. PubMed ID: 16323973
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of naftidrofuryl in patients with moderate senile dementia.
Saldmann F; Funel A; Jacquet P
Curr Med Res Opin; 1991; 12(6):379-89. PubMed ID: 2044398
[TBL] [Abstract][Full Text] [Related]
10. Naftidrofuryl can enhance the quality of life in patients with intermittent claudication.
Spengel F; Brown TM; Poth J; Lehert P
Vasa; 1999 Aug; 28(3):207-12. PubMed ID: 10483329
[TBL] [Abstract][Full Text] [Related]
11. Naftidrofuryl for dementia.
Lu D; Song H; Hao Z; Wu T; McCleery J
Cochrane Database Syst Rev; 2011 Dec; (12):CD002955. PubMed ID: 22161372
[TBL] [Abstract][Full Text] [Related]
12. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
Erkinjuntti T; Kurz A; Small GW; Bullock R; Lilienfeld S; Damaraju CV;
Clin Ther; 2003 Jun; 25(6):1765-82. PubMed ID: 12860497
[TBL] [Abstract][Full Text] [Related]
13. [Effect of naftidrofuryl (Praxilene) in primary open angle glaucoma: prospective double-blind study].
Beati D; Mermoud A; Faggioni R
Klin Monbl Augenheilkd; 1992 May; 200(5):407-8. PubMed ID: 1614112
[TBL] [Abstract][Full Text] [Related]
14. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.
Guekht AB; Moessler H; Novak PH; Gusev EI;
J Stroke Cerebrovasc Dis; 2011; 20(4):310-8. PubMed ID: 20656516
[TBL] [Abstract][Full Text] [Related]
15. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.
Marcusson J; Rother M; Kittner B; Rössner M; Smith RJ; Babic T; Folnegovic-Smalc V; Möller HJ; Labs KH
Dement Geriatr Cogn Disord; 1997; 8(5):320-8. PubMed ID: 9298634
[TBL] [Abstract][Full Text] [Related]
16. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial.
Pantoni L; Rossi R; Inzitari D; Bianchi C; Beneke M; Erkinjuntti T; Wallin A
J Neurol Sci; 2000 Apr; 175(2):124-34. PubMed ID: 10831773
[TBL] [Abstract][Full Text] [Related]
18. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials.
Román GC; Wilkinson DG; Doody RS; Black SE; Salloway SP; Schindler RJ
Dement Geriatr Cogn Disord; 2005; 20(6):338-44. PubMed ID: 16192723
[TBL] [Abstract][Full Text] [Related]
19. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg.
Adhoute G; Bacourt F; Barral M; Cardon JM; Chevalier JM; Cuny A; Gillet M; Juhan C; Leguay G; Marion J
Angiology; 1986 Mar; 37(3 Pt 1):160-7. PubMed ID: 3518547
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.
Moody AP; al-Khaffaf HS; Lehert P; Harris PL; Charlesworth D
J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S44-7. PubMed ID: 7517477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
